logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5667.produswest2
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5667.produswest2
Showing 1 - 7 of 7 Items
Showing 1 - 7 of 7 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Decentralised hepatitis C management: A simplified, integrated model of care in a primary health centre in Pakistan, August 2022-June 2023

Mazzilli S, Aslam MK, Ahmed M, Wailly Y, Miazek M,  et al.
2025-11-27 • Journal of Viral Hepatitis
2025-11-27 • Journal of Viral Hepatitis

Pakistan has the world's highest hepatitis C virus (HCV) prevalence, yet access to HCV care remains limited. In collaboration with the Ministry of Health Sindh, Médecins Sans Frontièr...

Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Commentary

Viral hepatitis and the global burden of disease: a need to regroup

Lemoine M, Thursz M, Gore C, Swan T, Kamarulzaman A,  et al.
2013-08-05 • Journal of Viral Hepatitis
2013-08-05 • Journal of Viral Hepatitis
Journal Article
|
Research
Journal Article
|
Research

Cost-effectiveness of screening and treatment using direct-acting antivirals for chronic Hepatitis C virus in a primary care setting in Karachi, Pakistan

Mafirakureva N, Lim AG, Khalid GG, Aslam K, Campbell L,  et al.
2020-11-04 • Journal of Viral Hepatitis
2020-11-04 • Journal of Viral Hepatitis
Despite the availability of effective direct-acting antiviral (DAA) treatments for Hepatitis C virus (HCV) infection, many people remain undiagnosed and untreated. We assessed the cost-e...

High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in Phnom Penh, Cambodia

Zhang M, O'Keefe D, Iwamoto M, Sann K, Kien A,  et al.
2020-05-02 • Journal of Viral Hepatitis
2020-05-02 • Journal of Viral Hepatitis
Safe and efficacious pan-genotypic direct-acting antiviral (DAA) regimens, such as sofosbuvir and daclatasvir (SOF+DCV) facilitate simplified models of care for hepatitis C virus (HCV). ...

Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral based treatment regimens: evidence from a global dataset

Morgan JR, Marsh E, Savinkina A, Shilton S, Shadaker S,  et al.
2022-03-12 • Journal of Viral Hepatitis
2022-03-12 • Journal of Viral Hepatitis
Achieving global elimination of hepatitis C virus requires a substantial scale-up of testing. Point-of-care HCV viral load assays are available as an alternative to laboratory-based assa...

Prevalence and vaccination coverage of Hepatitis B among healthcare workers in Cameroon: A national seroprevalence survey

Bilounga Ndongo C, Eteki L, Siedner MJ, Mbaye R, Chen JH,  et al.
2018-07-26 • Journal of Viral Hepatitis
2018-07-26 • Journal of Viral Hepatitis
Hepatitis B virus (HBV) infection is hyperendemic in Cameroon, and health care workers (HCWs) are at high-risk of infection. We aimed to assess prevalence, risk factors and vaccine cover...

Field evaluation of GeneXpert® (Cepheid) HCV performance for RNA quantification in a genotype 1 and 6 predominant patient population in Cambodia

Iwamoto M, Calzia A, Dublineau A, Rouet F, Nouhin J,  et al.
2018-12-03 • Journal of Viral Hepatitis
2018-12-03 • Journal of Viral Hepatitis
GeneXpert® (Cepheid) is the only WHO prequalified platform for hepatitis C virus (HCV) nucleic acid amplification testing that is suitable for point-of-care use in resource-limited conte...